ANAPTYSBIO INC. - COMMON STOCK

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

12 сен 2023 09:15:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

07 авг 2023 16:15:09 Источник Nasdaq GlobeNewswire

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

31 июл 2023 13:34:57 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Participation in Upcoming Investor Conferences

30 май 2023 16:15:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

11 май 2023 16:15:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

02 май 2023 09:15:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors

06 апр 2023 16:15:00 Источник Nasdaq GlobeNewswire

AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial

27 мар 2023 18:50:32 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

01 мар 2023 16:05:01 Источник Nasdaq GlobeNewswire

AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference

27 фев 2023 16:05:01 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Stock Repurchase Plan

13 янв 2023 09:00:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies

05 янв 2023 16:05:00 Источник Nasdaq GlobeNewswire

AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

02 дек 2022 09:00:00 Источник Nasdaq GlobeNewswire

AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference

21 ноя 2022 13:56:39 Источник Nasdaq GlobeNewswire

AnaptysBio to Participate in Upcoming November Investor Conferences

09 ноя 2022 14:10:17 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update

08 ноя 2022 16:05:01 Источник Nasdaq GlobeNewswire

AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials

05 окт 2022 09:00:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million

12 сен 2022 07:30:00 Источник Nasdaq GlobeNewswire

AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

31 авг 2022 16:15:00 Источник Nasdaq GlobeNewswire

AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update

08 авг 2022 16:05:03 Источник Nasdaq GlobeNewswire